Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00889070 · ClinicalTrials.gov registry record
Respiratory Events Among Premature Infants
A clinical trial of Respiratory Syncytial Virus, sponsored by MedImmune.
- Completed
- Registry status
- 50
- Enrollment target
- 5
- Study locations
NCT00889070 is a study of Respiratory Syncytial Virus that has completed, run by MedImmune. The registered enrollment target is 50 participants, below the 390-participant average among 7 other Respiratory Syncytial Virus trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT00889070, a study of Respiratory Syncytial Virus, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
Assess the burden of disease associated with RSV infection with premature children in an outpatient setting.
Conditions Studied
Study Locations (5)
California
- Children's Primary Care Medical Group, Inc. - San Diego
Florida
- North Florida Pediatrics - Lake City
Massachusetts
- Woburn Pediatric Associates - Woburn
New York
- Suny Upstate Medical University - Syracuse
Ohio
- Senders Pediatrics - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00889070
The ClinicalTrials.gov registry entry for NCT00889070 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 390-participant average among 7 other Respiratory Syncytial Virus trials with a reported enrollment target (87% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Respiratory Syncytial Virus appearing as the primary indexed condition, and to 0 interventions.
NCT00889070 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00889070 about?
NCT00889070 is a clinical study titled "Respiratory Events Among Premature Infants". Assess the burden of disease associated with RSV infection with premature children in an outpatient setting.
What is the current status of trial NCT00889070?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2008-11. Estimated completion is 2009-05.
What conditions does trial NCT00889070 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus.
Who is sponsoring clinical trial NCT00889070?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00889070 being conducted?
This trial has 5 study locations across California, Florida, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
ACTIVE NOT RECRUITING · Phase 3
-
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
ACTIVE NOT RECRUITING · Phase 2
-
Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults
COMPLETED · Phase 1
-
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.